Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 385, Issue 2, Pages 193-197Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2009.05.037
Keywords
beta-Amyloid; Alzheimer disease; Biomarker; Glucose; Insulin
Categories
Funding
- Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO)
- Japanese Ministry of Education, Culture, Sports, Science and Technology
- Japan Science and Technology Agency
- Takeda Science Foundation
Ask authors/readers for more resources
With the emergence of a promising approach to treat Alzheimer disease (AD) targeting the beta-amyloid (A beta) pathway, it is necessary to establish new diagnostic biomarkers that enable the antemortem diagnosis of AD. Although plasma A beta has been suggested as a non-invasive biomarker, its significance has been inconclusive. Thus, it is important to improve the diagnostic potential of plasma A beta. One of the potential approaches is to modify plasma A beta level using various modulators. In this study, we evaluated the influence of glucometabolic status on plasma A beta level in two lines of AD transgenic mouse. The present study demonstrated that plasma A beta level rapidly increased after glucose loading. More importantly, the magnitude of the increase in plasma A beta was significantly larger in AD transgenic mice than in wildtype littermates. These findings might Provide a novel diagnostic tool for AD using the elevation of plasma A beta level after glucose loading. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available